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Abstract 
Introduction. Genetic epidemiology is focused on the study of the genetic causes 
that determine health and diseases in populations. To achieve this goal a common 
strategy is to explore differences in genetic variability between diseased and non-
diseased individuals. Usual markers of genetic variability are single nucleotide 
polymorphisms (SNPs) which are changes in just one base in the genome. The 
usual statistical approach in genetic epidemiology study is a marginal analysis, 
where each SNP is analyzed separately for association with the phenotype. 
Motivation. It has been observed, that for common diseases the single-SNP 
analysis is not very powerful for detecting genetic causing variants. In this work, 
we consider Gene Set Analysis (GSA) as an alternative to standard marginal 
association approaches. GSA aims to assess the overall association of a set of 
genetic variants with a phenotype and has the potential to detect subtle effects of 
variants in a gene or a pathway that might be missed when assessed individually. 
Objective. We present a new optimized implementation of a pair of gene set 
analysis methodologies for analyze the individual evidence of SNPs in biological 
pathways. We perform a simulation study for exploring the power of the proposed 
methodologies in a set of scenarios with different number of causal SNPs under 
different effect sizes. In addition, we compare the results with the usual single-SNP 
analysis method. Moreover, we show the advantage of using the proposed gene set 
approaches in the context of an Alzheimer disease case-control study where we 
explore the Reelin signal pathway. 
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Chapter 1
Introduction and Goals
Genetic epidemiology is focused on the identification of genetic variants that
determine health and disease in populations, and also, in the study of how the genetic
variants interact with environmental factors. A common strategy is to explore
differences in genetic variability between diseased and non-diseased individuals
using single nucleotide polymorphisms (SNPs) as markers of the variability in a
genome region. The usual statistical approach in this kind of study is a marginal
analysis, where each SNP is analyzed separately for association with the phenotype.
We will refer to this as single-SNP analysis. When the number of SNPs to be
analyzed is very large, as in Genome Wide Association Studies (GWAS), the
multiple testing corrections that are required reduce dramatically the power of the
single-SNP strategy.
An alternative to single-SNP analysis is gene-set analysis (GSA) where the joint
effect of a set of M SNPs is measured. The set of SNPs that are jointly analyzed
may have a biological relationship, for instance, we may test for the joint effect
of SNPs within a gene or the joint effect of SNPs within a pathway. Thus, GSA
provides a combined association evidence of a set of SNPs (a gene-p-value or a
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pathway-p-value) which is meaningful and could be more powerful than single-SNP
analysis when the individual effects are small.
Our starting point is the Adaptive Rank Truncated Product method (ARTP)
proposed by Yu et. al, (2009)[22]. This GSA method consists on the combination
of the K smallest marginal p-values, where K is determined in an adaptive way.
One limitation of this approach, and also of other GSA methods, is that they
assume the same mode of inheritance for all the SNPs in the set (usually, the
additive model). But, the most important limitation is computational since the
final gene-set p-value relies on the nonparametric null distribution of the ARTP test
statistic which is estimated using permutational procedures. The main objective of
this work consists in improve these two important limitations.
Summarizing, the scientific archivements of this scientific proposal are the
following:
• We propose two alternative algorithms that improve the original ARTP
method [see Chapter 3]:
GSA-globalARTP: This method allows different modes of inheritance for
each SNPs in the set (max-statistic) using the same permutational proceduce
as in ARTP method, improving the first limitation.
GSA-globalEVT: This method reduces the computational requirements
fitting the ARTP statistic using the extreme value theory (EVT), also allowing
max-statistic test, improving both limitations mentioned.
• Moreover, we implement the proposed theorical algorithms into a R code
package (globalGSA1) [see Annex ].
1Available at: http://cran.r-project.org/web/packages/globalGSA/index.html
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• In addition, we perform a simulation study [see Chapter 4] to compare
the statistical power and the computational time among the proposed GSA
methods including also, the comparison with the results of single-SNP analysis
correcting for multiple testing using Benjamini-Hochberg method (Benjamini-
Hochberg, 1995 [3]).
• Finally, we apply these methodologies in the context of Alzheimer disease [see
Chapter 5] using the public GWAS data of Reiman et al., 2007 [14] study.
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Chapter 2
General concepts of genetic association
studies
The objective of Genetic Association Studies is to identify genetic variants that
explains the phenotype variability, and concretely, that modifies the risk of disease.
The most common genetic variation in the population is called single nucleotide
polymorphism (SNP) and the chromosomal location often called a locus. SNPs are
genetic variations in a DNA sequence that occurs when a single position in a genome
is altered. Most SNPs are biallelic polymorphisms, and it means that two possible
variants (alleles) are observed in the population at that specific locus. In the
majority of scenarios that we will consider, the marker locus has only two distinct
alleles, e.g., alleles A and a. Denoting by A the allele that is more frequent in the
population (wild-type or major allele) and by a the less frequent allele (minor or
variant allele), and taking into account that humans are diploid (each cell contains
two copies of the genome) each SNP locus can have three possible genotypes: AA
for major homozygous, Aa for heterozygous and aa for minor homozygous.
7
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2.1 Statistical genetic principles
Genomic Association studies are typically case–control designs where we consider
some individuals that are genotyped to detect nonrandom occurences between
each genotype frequency related to the two different stages of the disease. In this
context, we distinguish between cases and controls individuals. Such, binary traits
can be coded by Y , where Y = 1 denotes cases and Y = 0 denotes controls, and the
penetrance function (see Equation 2.1) represents probabilities for each considered
genotype G,
P (Y = 1 | G) + P (Y = 0 | G) = 0. (2.1)
In a statistical context, SNPs are expressed like categorical variables that
can always be coded in the form of numerical or indicator variables. Different
codifications of the genotypes correspond to different modes of inheritance as is
summarized in Table 2.1. In the dominant model, a single copy of the variant allele
Table 2.1: SNP codification under different inheritance modes.
Dominant Recessive Additive Codominant
Genotype G G G G1 G2
AA 0 0 0 0 0
Aa 1 0 1 1 0
aa 1 1 2 0 1
is sufficient to modify (increase or decrease) the risk of disease,
Pr(Y = 1 | G = Aa) = Pr(Y = 1 | G = aa). (2.2)
In contrast, in the recessive model two copies of the variant allele are necessary to
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modify the risk,
Pr(Y = 1 | G = Aa) = Pr(Y = 1 | G = AA). (2.3)
In the additive model, each copy of the variant allele confers an additive increase
(or decrease) in risk (in the appropriate disease risk scale). In this case, disease risk
is linearly related with the number of minor alleles. And finally, the most general
model is the codominant where the three genotypes have different effects on disease
risk,
Pr(Y = 1 | G = AA) 6= Pr(Y = 1 | G = Aa) 6= Pr(Y = 1 | G = aa). (2.4)
2.2 Statistical approaches for disease risk prediction
The usual strategy for considering disease models in Genomic Association Analysis
is marginal variable selection, defined in our work as single-SNP analysis. It tests
genetic association of individual SNPs and identifies only the most significant subset
that captures the majority of the information of genotype-phenotype association.
As we have described, for the human genetic setting, the genotype at a given
SNP has three levels: homozygous wildtype, heterozygous, and homozygous rare.
Considering a binary outcome, the data can be represented by the 2×3 contingency
table, and in this setting, a commonly used measure of association is the odds ratio
(OR) defined as the ratio of the odds of disease given a specific genotype to the
odds of disease among individuals without the specified genotype. Hence, each
locus is evaluated individually for its marginal association with disease performing
a marginal chi-square test where the genotypes with a p-value below a specified
threshold are included in the prediction model.
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Alternatively, a logistic regression model as in (see Equation 2.5) can be fitted
where G is the codification of the SNP as specified in Table 2.1, and Z represents
other non genetic covariates, where pi = Pr(Y = 1 | G, Z)
logit(pi) = β0 + β1G+ δZ (2.5)
In this model, exp(β1) is the odds-ratio of the group with G = 1 with respect to
the reference group.
However, it has been observed that the single-SNP analysis is not very powerful
for detecting genetic causing variants of common diseases; concretely most causal
SNPs effects are not detectable with the common single-SNP testing procedure
followed by correction for multiple comparisons, because the identified SNPs
represent only a small fraction of the genetic variants contributing to diseases under
study, and the majority of them represent statistical noise. Perhaps, we need to set
other focus of interest taking into account other forms of genomic modifications.
These drawbacks raise the possibility that genetic variants with a small individual
effects can have more jointly significant genetic impact.
10
Chapter 3
Gene Set Analysis
We consider Gene-set analysis to try to solve common limitations of single-SNP
analysis. Gene Set Analysis (GSA) as an alternative to single-SNP analysis that
could improve the power of genetic association studies by exploring functionally
and biologically meaningful sets of SNPs, corresponding to genes or pathways.
This strategy aims to obtain a more accurate measurement of association of a set
of genetic variants with a phenotype, and also provides the potential to detect
combined effects of SNPs in a gene or a pathway that might be missed doing a
marginal single analysis. Moreover, it reduces the multiple testing burden that
appears when performing a large number of single-SNP tests and it incorporates
biological knowledge in the statistical analysis, improving the statistical power to
detect causal genes.
3.1 Methods
In this work we consider two different approaches in order to combine the statistical
information obtained from the single-SNP tests starting from the idea of the
Adaptative Rank Truncated Product method (Yu, et al. 2009 [22]).
11
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3.1.1 Adaptive rank truncation product method
Adaptive Rank Truncated Product method (ARTP), is a GSA method for combining
the individual evidence of association over different SNPs within a gene or pathway
using the product of the K smallest marginal p-values
W
(b)
K =
Kj∏
i=1
p
(b)
(i) , 1 ≤ j. (3.1)
In the initial method RTP (Zaykin et al., 2002 [23]), the value K was fixed and
specified in advance, while in the ARTP method K is obtained in an adaptive way
and the gene-p-value is obtained from the permutational null distribution of WK .
The main goal of this work consists in improve some limitations of the origi-
nal ARTP algorithm. The first improvement consists in taking into account the
inheritance information of genetic variants, because, this an other GSA methods,
only consider p-values assuming an additive model. Following this idea, we propose
an improvement of the ARTP method by combining the p-values obtained from
the max-statistic test. We will refer to this as the globalARTP method.
3.1.2 Combining statistical tests by permutation procedure
The proposed methodology improves the original algorithms by introducing an
additional step where a global test for the best mode of inheritance of each SNP is
performed. Using the global adaptation it can be determined whether the global
pattern of a group of SNPs is significantly related to some phenotype of interest.
For easy of explanation we describe the proposed algorithms in the simplest case
where all M SNPs belong to the same set (gene). In this case, the algorithms
provide a gene-p-value which indicates if variation within the gene is associated
12
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with the phenotype. However, the implemented approach is more general and
allows the SNPs in the study to belong to different sets.
Algorithm
Step 1. Best genetic model: In terms of our proposed algorithm, the first step
performs an association analysis of each SNP with the phenotype, considering the
three different modes of inheritance (dominant, recessive, and additive) taking the
minimum of the three p-values, based on the likelihood ratio test. So, this first step
provides M p-values, one for each SNP in the gene, that are sorted increasingly:
p(1) ≤ p(2) ≤ . . . ≤ p(M). (3.2)
Step 2. Rank truncated product statistic: Given a value K ≤M , we would compute
the rank truncated product statistic Wk for each candidate truncation point k ≤ K
as defined in Equation 3.3. Indeed, in order to improve computational efficiency
and avoid computational problems we will work with the log transformation of Wk,
denoted by
Vk =
k∑
j=1
− log(p(j)), 1 ≤ k ≤ K. (3.3)
Step 3. Permutational null distribution of statistics Vk: We obtain the permutational
null distribution of Vk, 1 ≤ k ≤ K, under the null hypothesis that none of the M
SNPs in the gene are associated with the disease, by resampling the phenotype
variable B times and performing steps 1 and 2 on each permutated datasets. From
step 1, we obtain and sort the M single-SNP p-values corresponding to the best
inheritance mode of each SNP:
pb(1) ≤ pb(2) ≤ . . . ≤ pb(M), 0 ≤ b ≤ B, (3.4)
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where b = 0 corresponds to the original dataset. When performing step 2 we
obtain the test statistic, V
(b)
k , 1 ≤ k ≤ K, 0 ≤ b ≤ B. Significance of the
original test statistics can be explored by comparing V
(0)
k , 1 ≤ k ≤ K with
V
(b)
k , 1 ≤ k ≤ K, 1 ≤ b ≤ B. The following expression provides the permutational
p-values for statistics V
(0)
k , 1 ≤ k ≤ K under the null hypothesis:
Sˆ
(0)
k =
∑B
l=0 I(V
(l)
k ≥ V (0)k )
B + 1
, 1 ≤ k ≤ K. (3.5)
In fact, the algorithm requires the computation of the p-values not only for the
original statistics, but also for the permuted statistics, which are given by
Sˆ
(b)
k =
∑B
l=0 I(V
(l)
k ≥ V (b)k )
B + 1
, 1 ≤ k ≤ K, 1 ≤ b ≤ B. (3.6)
Step 4. Best truncated point: An additional step is to optimize the number k
of SNPs that are combined for each gene. For this we define k
(b)
opt, 0 ≤ b ≤ B as
the number k ∈ {1, . . . , K} that minimizes Sˆ(b)k , and this minimum is denoted as
minP (b):
minP (b) = min1≤k≤KS
(b)
k , 0 ≤ b ≤ B. (3.7)
Step 5. Gene-p-value: Finally, we estimate the gene-p-value by comparing the
original dataset minP (0) with the permuted datasets minP (b), 1 ≤ b ≤ B:
gene− p− value =
∑B
l=0 I(minP
(l) ≤ minP (0))
B + 1
, 0 ≤ b ≤ B. (3.8)
Still, an important limitation of both, the ARTP and the globalARTP methods,
is computational. Both rely on permutational procedures for estimating the
non parametric null distribution of the test statistic. Dudbridge et. al., (2004)
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proposed the use of the generalized extreme-value distribution for estimating the
null distribution of this statistic. The maximum likelihood estimation of the three
parameters (location, scale, and shape parameters) of the generalized extreme-value
distribution also requires the performance of a large number of permutations, but
much less than the nonparametric estimation and the tales of the distribution are
estimated more accurately.
Hence, we also propose an alternative algorithm, referred as globalEVT, for
estimating the null distribution of the ARTP statistic using the extreme-value theory
(EVT). This proposed method reduces importantly the computational requirements
since only one-parameter distributions are to be fitted. In addition, we improve the
statistical power of the globalEVT approach allowing different modes of inheritance
for each SNP in the set by using the Max-statistic test (Gonzalez et al., 2008 [8])
as in the previous proposed algorithm.
3.1.3 Combining statistical tests using Extreme-value theory
Considering the same notation as in the previous method, the proposed algorithm
is based on the following result:
Proposition 1. If U1, U2, · · · , UM are independent and identically distributed uni-
form random variables in the interval [0, 1], then the lth order statistic, denoted by
U(l), follows a Beta distribution Beta(l,M + 1− l) with density given by
fU(l)(u) =
M !
(l − 1)!(M − l)!u
l−1(1− u)u−l (3.9)
Assumption: We will also assume that when independence does not hold, that
is, when U1, U2, · · · , UM are dependent variables with standard Uniform distribution,
it is possible to find a number m∗ < M so that the distribution of the lth order
15
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statistic, U(l), is approximately a Beta distribution Beta(l,m
∗ + 1− l), where m∗ is
interpreted as the effective number of independent tests.
Taking these considerations, we propose the following algorithm for obtaining
the combined effect of a set of M SNPs:
Algorithm
Step 1. Best genetic model and transformation to uniformly distributed p-values:
The first step performs an association analysis of each SNP with the phenotype,
considering three different modes of inheritance (dominant, recessive, and additive)
and takes the minimum of the three likelihood ratio test p-values. So, this first
step provides M p-values, one for each SNP in the gene:
pminj = min{pdomj , precj , paddj }, j = 1, . . . ,M, (3.10)
where pdomj , p
rec
j and p
add
j are the p-values of j-SNP assuming a dominant, a
recessive and an additive model respectively. If the three test were independent the
distribution of pmin would follow a Beta(1, 3) distribution (see Proposition 1 with
l = 1 and M = 3), but, since the three tests are performed on the same SNP, the
three p-values are dependent and pmin follows a Beta(1, x) where x, the effective
number of tests, has been estimated to be equal to 2.2 (Sladek et al., 2007 [17]).
We transform pminj , j = 1, . . . ,M into values from a standard Uniform distribution
by applying the inverse distribution function:
rj = F
−1
Beta(1,x=2.2)(p
min
j ), j = 1, . . . ,M (3.11)
Step 2. Summarizing the k most associated SNPs: We sort increasingly the
uniformly distributed p-values obtained in step 1, considering the k best results for
16
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k ∈ {1, ...,M}. That is, we want to summarize the k first order statistics into a
unique statistic,
r(1) ≤ r(2) ≤ . . . ≤ r(M) (3.12)
If the SNPs were not correlated, the order statistics, r(j), follows a Beta distribution
Beta(j,M − j + 1), j ∈ {1, . . . , k}, but if the SNPs are correlated, the distribution
is Beta(j, y − j + 1), j ∈ {1, . . . , k}, where y is the effective number of tests.
We estimate y through a permutational approach. As in the previous step, we
transform the order statistics r(j), j = 1, . . . , k into values from a standard Uniform
distribution by applying their inverse distribution function:
tj = F
−1
Beta(j,y−j+1)(r(j)), j = 1, . . . , k (3.13)
As a summary statistic we take:
Sk = −2
k∑
j=1
log tj. (3.14)
As in Fisher’s method (Fisher, 1925 [7]), since tj are uniformly distributed, then
−2 log tj follow a chi-squared distribution with 2 degrees of freedom and, if the
k SNPs were uncorrelated the summary statistic Sk would follow a chi-squared
distribution with 2k degrees of freedom. Since the SNPs may be correlated, the
distribution of Sk is chi-squared distribution with ν degrees of freedom where ν
should be estimated through a permutational approach. We transform the sum
statistic Sk into a uniformly distributed value by applying its inverse distribution
function:
Uk = F
−1
Chi(ν)(Sk) (3.15)
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Step 3. Adaptive step: selection of the best truncation point: We repeat Step 2
for every k from 1 to K, where K is a specified truncation parameter. As a final
statistic gene set statistic we take the best of all:
W = min{U1, . . . , UK}. (3.16)
If the values Uk were independent and identically distributed (i.i.d), W follows a
Beta distribution Beta(1, K) but the Uk are correlated because they are calculated
as a cumulative sum of values, thus, it is necessary to approximate its distribution
by Beta(1, z), where z is the effective number of tests and is estimated using
a permutational procedure. Finally, the transformation of W to a uniformly
distributed valued provides the adjusted p-value for the set of M SNPs:
genesetpadjust = F
−1
Beta(1,z)(W ) (3.17)
Model fitting: The proposed model requires the estimation of three different
parameters; y, z, ν. We apply a permutational approach to estimating the first
two parameters taking into account the relationship between the mean and the
second shape parameter of a Beta distribution. Concretely, we reproduce a hundred
permutations of a Beta distribution, Beta(a, b), where the first shape parameter, a,
is known. Our purpose is estimate the second shape parameter, b, that is the total
number of effective tests (denoted by y and z in each case), as bˆ = µˆ−a
µˆ
.
On the other hand, in order to estimate ν, that is defined as the degrees of
freedom from a Chi squared fitted distribution, we also reproduce a permutational
procedure considering a hundred permutations, taking the mean from the permuted
values.
18
Chapter 4
Simulation study
4.1 Simulation design
We performed a simulation study with the goal of exploring the power and per-
formance of the proposed globalGSA methodology for detecting genes associated
with a phenotype. For this, we generated different scenarios corresponding to
balanced case-control studies with sample size N = 2, 000 (1,000 cases and 1,000
controls). We consider genes containing M independent SNPs (M = 10, 50, 100)
with a random minor allele frequency following a Beta distribution restricted to
the interval [0, 0.5] with mean equal to 0.2.
For generating the disease status we considered a disease prevalence equal to 0.2
and assumed that the first c SNPs in the dataset were causal SNPs with the same
effect size (RR = 1.2, 1.1), where RR is the relative risk of the heterozygous group
versus major homozygous group and the relative risk of the minor homozygous
group versus major homozygous group is RR2 (Urrea, et al., 2014 [20]).
We explore the size of the test in the case where there is no causal SNP (c = 0)
and the power of the test for detecting association at the gene-level in the scenarios
with c = 10 causal SNPs within the gene-set. This produces a total of twelve
19
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scenarios. For each scenario we compute the gene p-value using the globalARTP
algorithm allocating the number of permutations to B = 10, 000 and the truncation
point value equal to K = 10, and also, we compute the gene-p-value using the
globalEVT method considering B = 100 and K = 10. We repeat this process a
thousand of times for each scenario and we averaged the results over the thousand
replications providing the percentage of times (Pc) that the gene is significant (gene
p-value< 0.05).
Notice that GSA methods and single-SNP analysis are difficult to compare since
one is a gene-set approach providing just one p-value of the gene while the single-
SNP analysis provides several p-values related to the gene. But the comparison is
very important since it will indicate whether the gene-set analysis is more powerful
than the standard single-SNP approach or not. With this comparative goal, we
perform single-SNP analysis and declar that a gene was significantly associated with
the disease when at least one SNP in the gene was significant at the usual 0.05 level
after Benjamini and Holchberg multiple testing correction (Benjamini-Holchberg,
1995 [3]) for the M univariate tests performed in each gene.
4.2 Simulation results
Results are summarized in Tables 4.1 to 4.3. Table 4.1 provides the size of the tests,
that is the percentage of significant results when there is no causal SNP. While both
globalGSA methodologies control the size around the specified significance level
(5%), both, single-SNP results are rather conservative. Tables 4.2 and 4.3 provide
the power of the test, that is, the percentage of significant results (Pc) when there
are c = 10 causal SNPs within the M available SNPs in a gene. In Table 4.2 we can
compare the performance of the gene set analysis and single-SNP analysis when
the effect of the 10 causal SNPs is relatively high (RR = 1.2). When all SNPs in
20
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the gene are causal (M = c = 10), all the methods cosidered are very powerful to
detect association of the gene. When the number M of SNPs in the gene increases
to 50 and 100 the globalARTP methods are still very powerful (Pc = 100%) while
we can observe a slight decrease in the power of single-SNP analysis due to the
multiple testing correction: Pc = 96% and Pc = 93%. If we focus on the globalEVT
results we can observe that there are similar to those arising from the single-SNP
analysis, and lower than the globalARTP results. However, if we consider the
computational time, globalEVT becomes more quicker.
In Table 4.3 we can compare the results when the marginal risk effect of each
individual causal SNPs is very small (RR = 1.1). The gene-based approaches
are clearly more powerful than the single-SNP analysis. The increase in power
is very evident when all SNPs in the gene are causal. In this case the advantage
of globalGSA over the single-SNP analysis is approximately larger than 30% in
globalARTP method, and larger than 15% in globalEVT method. However, when
the relative risks are so small, the inclusion of noise (null SNPs in the gene when
M = 50 and M = 100) reduces the power of all considered approaches, although
globalGSA methods are still above single-SNP analysis results.
In summary, globalGSA methods are more powerful than single-SNP analysis
in all different considered scenarios. Furthermore, globalGSA adapted methods
reduce the lost of power produced by the multiple testing correction, and allows
the incorporation of biological knowledge too. Results obtained by comparing
globalGSA methods suggest that the adapted approaches have a similar behavior.
On the other hand, if we compare the two different consireded GSA strategies, we
can see that globalARTP is slightly above globalEVT as far as association risk
detection is concerned. However, in order to obtain an acceptable level of statistical
21
Chapter 4. Simulation study
Table 4.1: Size of the tests
Methodology M = 10 M = 50 M = 100
globalARTP c = 0 5.3% 4.5% 2.4%
globalEVT c = 0 3.5% 5.1% 2.8%
FDR c = 0 4.1% 1.1% 1.8%
Table 4.2: Power of the tests when RR = 1.2
Methodology M = 10 M = 50 M = 100
globalARTP c = 10 100% 100% 100%
globalEVT c = 10 100% 98.5% 97.1%
FDR c = 10 100% 96.2% 93.4%
Table 4.3: Power of the tests when RR = 1.1
Methodology M = 10 M = 50 M = 100
globalARTP c = 10 79.7% 34.6% 33.2%
globalEVT c = 10 55.7% 34.2% 33.1%
FDR c = 10 42.9% 20.1% 11.8%
significance, permutational procedures require a high number of permutations (at
least 10,000 permutations to obtain a significance level of 1e − 04). Even if we
are rigorous, as we are working in a genetic context, the required significance level
should be 1e− 07 needing in this case a total of 10,000,000 permutations, that are
very expensive (maybe impossible) to compute. So, if we taking into account the
computational time, in order to obtain a suitable level of statistical significance,
globalEVT becomes much more efficient.
In conclusion, the GSA proposed methods increases the statistical power in
genetic association studies compared with single-SNP analysis. Moreover, the use
of extreme-value distribution (EVT) produce a reduction in computation compared
with a standard permutation test, and this can be translate to significant time
savings.
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Alzheimer disease application
We apply the proposed methodologies to an Alzheimer disease study for determining
which genes are associated with Reelin signal, a protein that is thought to be related
with an increase risk of Alzheimer disease (Rice et al., 2001 [15]; Tissir et al.,
2003 [19]). In this context we compare the gene set analysis proposed approaches
with the usual single-SNP analysis results.
5.1 Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder without cure that aﬄects
an increasing part of our ageing population. It was described by Alois Alzheimer in
1906 (Alzheimer, 1906 [1]) and it is characterized by amyloid plaques, neurofibrillary
tangles and loss of synapses (Berchtold et al., 1998 [4]). Alzheimer’s disease is
usually diagnosed clinically based on the presence of neurological characteristics and
neuropsychological features. However an accurate diagnosis can only be obtained
post-mortem when brain material is available and can be examined histologicaly,
as is extensively explained in (Nussbaum et al., 2003 [13].
We still know very little about the etiology of Alzheimer’s disease but it is clear
that there is a genetic component. Some genes have been associated with AD
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as amyloid precursor protein (APP) and presenilins 1 (PSEN1) and 2 (PSEN2)
(Waring et al., 2008 [21]). But, in fact, the best known genetic risk factor is the
inheritance of the e4 allele of the apolipoprotein E gene (APOE). It has been
demonstrated that between 50%− 80% of people with Alzheimer disease carry at
least one APOE-e4 allele (Mahley et al., 2006 [12]); Strittmatter et al., 1993 [18]).
APOE occurs in 3 common isoforms (E2, E3, E4) in the human population and
APOE-e4 is the primary genetic risk factor for late-onset Alzheimer’s disease. This
strong genetic association suggest that APOE receptors are very related with the
Alzheimer’s Disease patogenesis (Herz et al., 2000 [10]; Herz et al., 2006 [11]). In
addition to these well known genes, other genetic pathways, as the Reelin pathway,
are currently investigated for their association with the risk of AD.
5.2 Importance of Reelin in Alzheimer disease
Many studies connect Reelin protein with Alzheimer disease (Botella-Lo´pez et al.,
2006 [5]; Baloyannis, 2005 [2]; Saez-Valero et al., 2003 [16]). Clinical investigations
have shown that Reelin plays an eminent role at the most active neurogenesis sites
in interaction with APOE protein. According with many studies, Reelin expression
is altered in Alzheimer’s disease. In the cortex of the patients, Reelin levels were
40% higher compared with controls, but the cerebella levels of the protein remain
normal in the same patients. These evidences drives to the hypothesis that an
inappropriate activation of Reelin signal can be associated with cellular harm and
cellular death.
The objective and motivation of this application is to use our new implented
GSA approaches, globalARTP and globalEVT, to derive gene-level association
signals of the Reelin pathway with AD and compare these results with single-SNP
analysis.
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5.3 Descriptive Information
The data for this study is extracted from a public GWAS from Reiman et al.,
2007 [14], reporting 312,316 SNPs in a case-control study with 1411 individuals
(861 cases, 550 controls). An exhaustive analysis about the Reelin signal pathway
was carried out using Biomart website (http://www.biomart.org), identifying 32
genes in this pathway (682 SNPs). Data information can be consulted on Table
5.1. It contains the gene’s name, the chromosome, the strand, the staffed position,
the length and the promotor’s position. Also, we have information about APOE
genotypes. We can observe in Table 5.2 and in Figure 5.1 that 80% of individuals
with at least one copy of the e4 allele were affected by the disease.
Figure 5.1: Cases and controls Apoe genotypes distribution.
This percentage increase more than 90% for individuals with two e4 alleles and
it decreases until 50%, for non APOE-e4 carriers.
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Table 5.1: Genomic data information.
Gene Chr no SNPs Str bp1 bp2 length
Abl1 9 27 + 132578987 132752883 173896
Abl2 1 8 - 177335085 177465155 130070
ApoE 19 11 + 50100879 50104489 3610
APP 21 50 - 26174733 26465003 290270
Bdnf 11 6 - 27633016 27700181 67165
CDC42 1 12 + 22235157 22292024 56867
Cdk5 7 4 - 150381832 150385929 4097
CNR1 6 8 - 88906302 88932385 26083
Dab1 1 252 - 57233039 58488763 1255724
Emx2 10 1 + 119291946 119299043 7097
EPHA1 7 3 - 142798331 142816107 17776
Fyn 6 37 - 112089190 112301320 212130
GSK3B 3 7 - 121028238 121295954 267716
itga3 17 10 + 45488488 45522842 34354
LDLR 19 4 + 11061132 11105490 44358
LRP2 2 44 - 169691865 169927368 235503
TP73 1 4 + 3558989 3639716 80727
AKT1 14 3 - 104306734 104333125 26391
PLK2 5 1 - 57785571 57791670 6099
PSEN1 14 4 + 72672908 72756862 83954
PSEN2 1 6 + 225124896 225150429 25533
RAC1 7 5 + 6380651 6410123 29472
Reln 7 83 - 102899473 103417198 517725
Rho 3 3 + 130730172 130736867 6695
RHOA 3 4 - 49371585 49424530 52945
INPP5D 2 18 + 233633433 233781287 147854
Src 20 4 + 35407971 35467867 59896
MAPT 17 31 + 41327624 41461547 133923
VLDLR 9 7 + 2611793 2644485 32692
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Table 5.2: Cases and controls Apoe genotypes distribution.
Controls Cases
Allele e2e2 85.71 14.29
Allele e2e3 71.43 28.57
Allele e2e4 19.51 80.49
Allele e3e3 53.44 46.56
Allele e3e4 21.70 78.30
Allele e4e4 5.30 94.70
Non-e4 carriers 56.45 43.55
e4 carriers 18.20 81.80
5.4 Statistical analysis
5.4.1 single-SNP analysis
In this step we perform a marginal association analysis of each SNP with the
phenotype (where we consider Y = 1 as an affected individual, and Y = 0 as a
control individual). Since carriers of APOE-e4 variant have an increased risk of
disease, we should consider this in the marginal analysis. Specifically, we define
the APOE indicator variable (IndApoe) as the indicator for those individuals
carrying at least one copy of APOE-e4. Then, we analyze three different datasets;
all individuals adjusting by APOE Indicator variable, non APOE carriers, and
APOE carriers. Since the response is dichotomous (status: case/control) we adjust
a logistic regression model using the GWassociation function from SNPassoc
R package (Gonzalez, et al., 2007 [9]). This function provides SNPs’ p-values
considering different inheritance modes (dominant, codominant, recessive and
additive).
With a significance level equal to 1%, we obtain 13 significant SNPs for the
adjusted model without multiple testing correction (see Table 5.3), 11 significant
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SNPs for carriers (see Table 5.4) and 20 significant SNPs for non-carriers (see Table
5.5). But, if we correct the results using Benjamini-Holchberg method (Benjamini-
Holchberg, 1995 [3]), all the SNPs become non-significant. Hence, in summary,
single-SNP analysis is not able to identify any genetic variant in the Reelin pathway
that is significantly associated with Alzheimer’s disease.
Figure 5.2: Manhattan plots.
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Figure 5.3: Manhattan plots.
Figure 5.4: Manhattan plots.
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Table 5.3: Significant SNPs without multiple correction all individuals.
Gene codominant dominant recessive additive p min p adjust
rs17416642 DAB1 1.35e-02 6.30e-03 5.30e-01 1.08e-02 6.30e-03 0.387
rs17115767 DAB1 2.32e-02 5.07e-01 6.16e-03 2.18e-01 6.16e-03 0.387
rs10493223 DAB1 3.30e-04 2.21e-01 7.38e-02 5.11e-02 3.30e-04 0.047*
rs1404388 DAB1 9.08e-03 9.08e-03 0.387
rs10493230 DAB1 8.88e-03 1.13e-02 3.38e-01 1.03e-01 8.88e-03 0.387
rs1202774 DAB1 2.17e-03 7.50e-01 6.47e-04 8.23e-01 6.47e-04 0.147
rs4448540 DAB1 5.44e-04 5.44e-04 0.147
rs16845844 PSMD14 1.05e-02 4.22e-01 2.58e-03 1.42e-01 2.58e-03 0.292
rs2193193 LRP2 2.75e-02 2.35e-01 7.88e-03 1.89e-02 7.88e-03 0.387
rs2239594 LRP2 9.28e-03 2.18e-02 7.87e-03 2.44e-03 2.44e-03 0.292
rs830959 LRP2 1.12e-02 5.31e-03 5.19e-02 3.34e-03 3.34e-03 0.324
rs17111118 ARSI 1.94e-02 8.74e-03 7.67e-01 2.42e-02 8.74e-03 0.387
rs11030102 BDNF 1.24e-03 3.22e-01 2.22e-03 6.99e-01 1.24e-03 0.211
Table 5.4: Significant SNPs without multiple correction Apoe4 carriers.
Gene codominant dominant recessive additive p min p adjust
rs10917139 CDC42 6.16e-03 6.95e-01 2.96e-03 6.01e-01 2.96e-03 0.551
rs6680219 DAB1 1.34e-02 3.24e-01 3.32e-03 1.80e-02 3.32e-03 0.551
rs17482980 DAB1 1.05e-02 2.16e-03 1.00 1.05e-02 2.16e-03 0.551
rs10493230 DAB1 8.06e-03 6.94e-02 5.35e-02 5.26e-01 8.06e-03 0.551
rs1202774 DAB1 4.26e-03 1.22e-01 3.13e-02 4.26e-03 4.26e-03 0.551
rs4448540 DAB1 8.51e-03 8.51e-03 0.551
rs6663243 DAB1 3.07e-02 1.20e-02 1.27e-01 8.64e-03 8.64e-03 0.551
rs6668200 ABL2 2.61e-02 9.65e-01 9.07e-03 4.35e-01 9.07e-03 0.551
rs16845844 PSMD14 9.20e-03 2.11e-02 1.17e-02 5.24e-03 5.24e-03 0.551
rs11689553 LRP2 9.21e-03 2.17e-02 1.60e-01 1.54e-01 9.21e-03 0.551
rs7752758 CNR1 1.98e-02 5.83e-03 2.77e-01 5.35e-03 5.35e-03 0.551
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Table 5.5: Significant SNPs without multiple correction non-Apoe4 carriers.
Gene codominant dominant recessive additive p min p adjust
rs17416642 DAB1 2.47e-03 2.47e-03 0.274
rs10493223 DAB1 4.85e-03 1.46e-01 2.82e-03 4.85e-03 2.82e-03 0.274
rs17472030 DAB1 7.08e-03 1.34e-02 2.55e-01 1.08e-01 7.08e-03 0.279
rs11207103 DAB1 6.70e-03 6.19e-03 4.96e-01 4.56e-02 6.19e-03 0.279
rs12143653 DAB1 7.77e-03 9.33e-03 3.89e-01 6.95e-02 7.77e-03 0.279
rs2052297 LRP2 2.51e-02 2.78e-01 6.86e-03 2.06e-02 6.86e-03 0.279
rs2193193 LRP2 9.06e-03 6.96e-02 3.36e-03 3.64e-03 3.36e-03 0.279
rs2268370 LRP2 2.51e-02 3.28e-02 2.29e-02 7.03e-03 7.03e-03 0.279
rs2239594 LRP2 2.25e-02 1.28e-01 7.58e-03 1.10e-02 7.58e-03 0.279
rs16856748 LRP2 6.73e-04 3.03e-04 6.98e-01 1.62e-03 3.03e-04 0.206
rs830955 LRP2 2.16e-02 2.06e-02 3.29e-02 5.99e-03 5.99e-03 0.279
rs11792273 ABL1 2.58e-02 9.90e-03 1.99e-01 7.20e-03 7.20e-03 0.279
rs6018100 SRC 7.03e-03 1.00e+00 2.25e-03 3.91e-01 2.25e-03 0.274
rs2830073 APP 1.73e-02 5.59e-03 1.18e-01 7.01e-03 5.59e-03 0.279
rs2830075 APP 8.47e-03 2.65e-03 1.37e-01 2.41e-03 2.41e-03 0.274
rs2830076 APP 9.41e-03 6.42e-03 3.49e-02 2.26e-03 2.26e-03 0.274
rs432766 APP 1.51e-02 8.90e-03 4.05e-02 4.02e-03 4.02e-03 0.279
rs375369 APP 1.72e-02 9.84e-03 5.01e-02 4.79e-03 4.79e-03 0.279
rs2186302 APP 3.12e-02 1.19e-02 1.46e-01 8.91e-03 8.91e-03 0.303
rs436011 APP 5.93e-03 7.00e-03 1.46e-02 1.48e-03 1.48e-03 0.274
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5.4.2 Gene Set Analysis
The proposed globalARTP and globalEVT methods, as GSA approaches, estimate
the joint effect of all genetic variants in each gene. So, we use the to obtaining
significative genes associated with Alzheimer disease. For globalARTP method, we
fix B = 10, 000 permutated data sets and K = 10 as the truncation point. For
globalEVT we fix B = 100 permutations and also K = 10 as a truncation point.
The results are given in Tables 5.6, 5.7 and 5.8. Table 5.9 provides a summary of
the significatively associated genes identified with both methodologies.
Applying globalARTP we obtain that the most significative genes are Bdnf
and Tbr1, for APOE-e4 carriers the only significative gene is CNR1, while, for
non-APOE-e4 carriers model the most important gens is Src. Applying globalEVT
we obtain that the most significative genes are Dab1, Bdnf, AKT1 and Cdk5 for all
individuals, Dab1 for carriers model, and LRP2, Src for non carriers model.
Table 5.9: GlobalGSA Results
Methodology
Model globalARTP globalEVT
All individuals Bdnf,Tbr1 Dab1, Bdnf, AKT1, CDK5
Apoe4 carriers CNR1 Dab1
Non-Apoe4 carriers Src Src, LRP2
In conclusion, we can observe while using the single-SNP analysis we don’t
find statistical significance after multiple testing correction, our proposed GSA
methodologies get to capture some genes that are associated with Alzheimer disease.
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Table 5.6: GSA adjusted model results
Gene globalARTP pvalue globalEVT pvalue
TP73 0.75 0.994
CDC42 0.53 1
ApoER2 0.88 1
Dab1 0.07 2.184e-41
Abl2 0.17 0.991
PSEN2 0.47 0.999
Tbr1 0.04 0.954
LRP2 0.13 0.999
SHIP 0.48 0.999
RHOA 0.21 0.999
GSK3B 0.58 0.999
Rho 0.30 0.661
PIK3R1 0.91 0.999
CAMK2A 0.27 0.997
CNR1 0.62 0.999
Fyn 0.48 0.999
RAC1 0.33 0.932
Reln 0.94 0.999
EPHA1 0.80 0.999
Cdk5 0.28 0.031
VLDLR 0.43 0.993
Abl1 0.44 0.999
Bdnf 0.02 0.008
PSEN1 0.68 0.999
AKT1 0.25 0.039
Tau 0.54 0.999
itga3 0.69 0.999
LDLR 0.64 0.771
Src 0.31 0.999
APP 0.45 0.999
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Table 5.7: GSA APOE-e4 carriers model results
Gene globalARTP pvalue globalEVT pvalue
TP73 0.49 0.999
CDC42 0.09 0.703
ApoER2 0.25 0.999
Dab1 0.51 0.0295
Abl2 0.13 0.999
PSEN2 0.61 0.999
Tbr1 0.08 0.623
LRP2 0.58 1
SHIP 0.73 0.999
RHOA 0.49 0.993
GSK3B 0.31 0.929
Rho 0.13 0.057
PIK3R1 0.84 1
CAMK2A 0.92 0.999
CNR1 0.05 0.561
Fyn 0.87 0.999
RAC1 0.63 0.999
Reln 0.89 0.999
EPHA1 0.26 0.824
Cdk5 0.34 0.501
VLDLR 0.74 0.999
Abl1 0.95 1
Bdnf 0.21 0.994
PSEN1 0.26 0.921
AKT1 0.26 0.155
Tau 0.33 0.999
itga3 0.91 0.999
LDLR 0.93 0.999
Src 0.51 0.999
APP 0.70 0.999
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Table 5.8: GSA APOE-e4 non carriers model results
Gene globalARTP pvalue globalEVT pvalue
TP73 0.52 0.664
CDC42 0.55 0.999
ApoER2 1.00 1
Dab1 0.58 0.999
Abl2 0.29 0.994
PSEN2 0.14 0.901
Tbr1 0.51 0.999
LRP2 0.06 5.38e-13
SHIP 0.40 0.999
RHOA 0.60 0.991
GSK3B 0.56 0.999
Rho 0.85 0.973
PIK3R1 0.72 0.999
CAMK2A 0.26 0.986
CNR1 0.36 0.904
Fyn 0.64 0.999
RAC1 0.52 0.997
Reln 0.83 1
EPHA1 0.93 0.781
Cdk5 0.50 0.982
VLDLR 0.67 0.999
Abl1 0.22 0.986
Bdnf 0.19 0.855
PSEN1 0.98 0.999
AKT1 0.84 0.991
Tau 0.52 1
itga3 0.84 1
LDLR 0.42 0.564
Src 0.04 9.16e-06
APP 0.05 0.915
35
Chapter 5. Alzheimer disease application
36
Chapter 6
Discussion
In this project we center on Gene Set Analysis (GSA), a strategy for combining
the effects of many genetic variants within a gene. We propose the algorithms
globalARTP and globalEVT, as a new implementations of the ARTP method
that are specifically designed for genetic association studies involving SNPs. New
implementation incorporates the selection of the best inheritance model for each
SNP as a first step of the algorithm, and in the case of globalEVT, the computational
time required is improved.
Through a simulation study we proved that Gene Set Analysis proposed ap-
proaches increase the power to detect genetic associations when the individual
effects are very small, which is the usual case in complex diseases. In this situation,
most causal SNPs effects are not detectable with the common single-SNP testing
procedure followed by correction for multiple comparisons. By combining the
p-values of a set of SNPs in a gene we reduce the number of tests, and thus the
multiple testing corrections needed. Moreover, in many cases, the association results
given at the gene level may be more biologically interpretable. We also applied
GSA in a real case in the context of Alzheimer’s disease. While the single-SNP
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analysis does not detect any association at the univariate level, GSA detects some
interesting genes that are worth further investigating.
Hence, in conclusion, obtained results show that the two proposed new method-
ologies increase significantly statistical power opposite to single-SNP analysis and,
concretely, the second proposed method (globalEVT) reduces importantly the
computational requirements since only one-parameter distributions are to be fitted.
But, GSA has also some limitations. This strategy will only be useful in the
presence of marginal effects. However, it will not be effective when the genetic
association is due to gene interactions without marginal individual effects. This will
require specific methods for gene-gene interaction detection such as the MB-MDR
method (Calle et al., 2010 [6]).
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This function provides the p-value for a joint test of association between a phenotype and a set
of genetic variants (SNPs) using the Adaptive Rank Truncated Product method [1] after a global
test for the best mode of inheritance of every SNP. The final gene-p-value is obtained from the
permutational null distribution of the test statistic.
Usage
globalARTP(data, B, K, gene_list, Gene = "all", addit = FALSE,
covariable = NULL, family = binomial)
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Arguments
data Data frame containing the variables in the model. The first column is the depen-
dent variable which must be a binary variable defined as factor (in case-control
studies, the usual codification is 1 for cases and 0 for controls). SNP values may
be codified in a numerical form (0,1,2) denoting the number of minor alleles, or
using a character form where the two alleles are specified, without spaces, tabs
or any other symbol between the two alleles.
B Number of permutations considered in the permutational procedure.
K Integer that indicates the maximum truncation point.
gene_list File that provides the name of the set (for instance, gene) where each SNP be-
longs. This file has two columns: the SNP-Id ("Id"), and the Gene-Id ("Gene").
The SNP-Id must have the same label as the colnames of the data file.
Gene Name of the gene that we want to analyze. The default value is Gene= "all"
that indicates that the p-values of all SNPs in the database are to be combined.
In this case it is not necessary to specify the gene_list file. In other case, we
need to specify the name of the gene, for instance, Gene = "Gene1", and also the
gene_list file.
addit logical to determine if only an additive inheritance model should be considered
in the global Test or, conversely, if we want to consider all possible inheritance
models (dominant, recessive, log-additive and co-dominant). By default, addit
= FALSE.
covariable Data frame containing the covariables in the model. Each column represents
one covariable. By default, covariable=NULL.
family This can be a character string naming a family distribution. By default, fam-
ily=binomial.
Value
List with the following components:
nPerm Number of permutations.
Gene Considered Gene.
Trunkpoint Considered truncation point.
Kopt Optimal truncation point.
genevalue gene-pvalue.
References
[3] Yu, K. Li, Q. Bergen, A.W. Pfeiffer, R.M. Rosenberg, P.S. Caporaso, N. Kraft, P. and Chatter-
jee,N. (2009). Pathway analysis by adaptive combination of P-values. Genet, Epidemiol. Decem-
ber; 33(8): 700-709.
Examples
# load the included example dataset.
# This is a simulated case/control study data set
# with 2000 patients (1000 cases / 1000 controls)
# and 10 SNPs, where all of them have
# a direct association with the outcome:
data(data)
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#globalARTP(data, B=1000, K=10, Gene="all", addit = FALSE)
# it may take some time,
# hence the result of this example is included:
data(ans11)
# You can test:
globalARTP(data, B=1, K=10, Gene="all", addit = FALSE)
# We consider that the first four SNPs
# are included in "Gene1",
# and the other six SNPs
# are included in "Gene2":
data(gene_list)
#globalARTP(data, B=1000, K=10, gene_list=gene_list, Gene="Gene1", addit = FALSE)
# it may take some time,
# hence the result of this example is included:
data(ans1)
# You can test:
globalARTP(data, B=1, K=10, gene_list=gene_list, Gene="Gene1", addit = FALSE)
globalEVT Global Adaptive Extreme Value Distribution method.
Description
This function provides the p-value for a joint test of association between a phenotype and a set of
genetic variants (SNPs) using an Adaptive Extreme Value Distribution after a global test for the best
mode of inheritance of every SNP. The final gene-p-value is obtained from
Usage
globalEVT(data, K)
Arguments
data Data frame containing the variables in the model. The first column is the depen-
dent variable which must be a binary variable defined as factor (in case-control
studies, the usual codification is 1 for cases and 0 for controls). SNP values may
be codified in a numerical form (0,1,2) denoting the number of minor alleles, or
using a character form where the two alleles are specified, without spaces, tabs
or any other symbol between the two alleles.
K Integer that indicates the maximum truncation point.
Value
List with the following components:
genevalue gene-pvalue.
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Examples
# load the included example dataset.
# This is a simulated case/control study data set
# with 2000 patients (1000 cases / 1000 controls)
# and 10 SNPs, where all of them have
# a direct association with the outcome:
data(data)
globalEVT(data, K=10)
globalFisher Global Fisher combination method.
Description
This function provides the p-value for a joint test of association between a phenotype and a set
of genetic variants (SNPs) using the Fisher method [1] after a global test for the best mode of
inheritance of every SNP. The final gene-p-value is obtained from the permutational null distribution
of the test statistic
Usage
globalFisher(data, B, gene_list, Gene = "all", addit = FALSE,
covariable = NULL, family = binomial)
Arguments
data Data frame containing the variables in the model. The first column is the depen-
dent variable which must be a binary variable defined as factor (in case-control
studies, the usual codification is 1 for cases and 0 for controls). SNP values may
be codified in a numerical form (0,1,2) denoting the number of minor alleles, or
using a character form where the two alleles are specified, without spaces, tabs
or any other symbol between the two alleles.
B Number of permutations considered in the permutational procedure.
gene_list File that provides the name of the set (for instance, gene) where each SNP be-
longs. This file has two columns: the SNP-Id ("Id"), and the Gene-Id ("Gene").
The SNP-Id must have the same label as the colnames of the data file.
Gene Name of the gene that we want to analyze. The default value is Gene= "all"
that indicates that the p-values of all SNPs in the database are to be combined.
In this case it is not necessary to specify the gene_list file. In other case, we
need to specify the name of the gene, for instance, Gene = "Gene1", and also the
gene_list file.
addit logical to determine if only an additive inheritance model should be considered
in the global Test or, conversely, if we want to consider all possible inheritance
models (dominant, recessive, log-additive and co-dominant). By default, addit
= FALSE.
covariable Data frame containing the covariables in the model. Each column represents
one covariable. By default, covariable=NULL.
family This can be a character string naming a family distribution. By default, fam-
ily=binomial.
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Value
List with the following components:
nPerm Number of permutations.
Gene Considered Gene.
genevalue gene-pvalue.
References
[1] Fisher, R.A. (1925). Statistical Methods for Research Workers. ISBN 0-05-002170-2.
Examples
# load the included example dataset.
# This is a simulated case/control study data set
# with 2000 patients (1000 cases / 1000 controls)
# and 10 SNPs, where all of them have
# a direct association with the outcome:
data(data)
#globalFisher(data, B=1000, Gene="all", addit=FALSE)
# it may take some time,
# hence the result of this example is included:
data(ans21)
# You can test:
globalFisher(data, B=1, Gene="all", addit=FALSE)
# We consider that the first four SNPs
# are included in "Gene1",
# and the other six SNPs
# are included in "Gene2":
data(gene_list)
#globalFisher(data, B=1000, gene_list=gene_list, Gene="Gene1", addit=FALSE)
# it may take some time,
# hence the result of this example is included:
data(ans2)
# You can test:
globalFisher(data, B=1, gene_list=gene_list, Gene="Gene1", addit=FALSE)
globalSimes Global Simes’ combination method.
Description
This function provides the p-value for a joint test of association between a phenotype and a set
of genetic variants (SNPs) using the Simes method [1] after a global test for the best mode of
inheritance of every SNP. The final gene-p-value is obtained from the permutational null distribution
of the test statistic
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Usage
globalSimes(data, B, gene_list, Gene = "all", addit = FALSE,
covariable = NULL, family = binomial)
Arguments
data Data frame containing the variables in the model. The first column is the depen-
dent variable which must be a binary variable defined as factor (in case-control
studies, the usual codification is 1 for cases and 0 for controls). SNP values may
be codified in a numerical form (0,1,2) denoting the number of minor alleles, or
using a character form where the two alleles are specified, without spaces, tabs
or any other symbol between the two alleles.
B Number of permutations considered in the permutational procedure.
gene_list File that provides the name of the set (for instance, gene) where each SNP be-
longs. This file has two columns: the SNP-Id ("Id"), and the Gene-Id ("Gene").
The SNP-Id must have the same label as the colnames of the data file.
Gene Name of the gene that we want to analyze. The default value is Gene= "all"
that indicates that the p-values of all SNPs in the database are to be combined.
In this case it is not necessary to specify the gene_list file. In other case, we
need to specify the name of the gene, for instance, Gene = "Gene1", and also the
gene_list file.
addit logical to determine if only an additive inheritance model should be considered
in the global Test or, conversely, if we want to consider all possible inheritance
models (dominant, recessive, log-additive and co-dominant). By default, addit
= FALSE.
covariable Data frame containing the covariables in the model. Each column represents
one covariable. By default, covariable=NULL.
family This can be a character string naming a family distribution. By default, fam-
ily=binomial.
Value
List with the following components:
nPerm Number of permutations.
Gene Considered Gene.
genevalue gene-pvalue.
References
[1] Simes, R.J. (1986). An Improved Bonferroni Procedure for Multiple Tests of Significance.
Biometrika, 73, 751-754.
Examples
# load the included example dataset.
# This is a simulated case/control study data set
# with 2000 patients (1000 cases / 1000 controls)
# and 10 SNPs, where all of them have
# a direct association with the outcome:
data(data)
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#globalSimes(data, B=1000, Gene="all", addit=FALSE)
# it may take some time,
# hence the result of this example is included:
data(ans31)
# You can test:
globalSimes(data, B=1, Gene="all", addit=FALSE)
# We consider that the first four SNPs
# are included in "Gene1",
# and the other six SNPs
# are included in "Gene2":
data(gene_list)
#globalSimes(data, B=1000, gene_list=gene_list, Gene="Gene1", addit=FALSE)
# it may take some time,
# hence the result of this example is included:
data(ans3)
# You can test:
globalSimes(data, B=1, gene_list=gene_list, Gene="Gene1", addit=FALSE)
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